Genervon to Award Price for Scientists Proposing Medical Indications and Trial Protocols - Genervon GrandChallenges (G2C)

| Print |
Thursday, 23 February 2012 15:00 (UTC + 1)

Genervon_logo

Pasadena, USA, February 23, 2012 / B3C newswire / - Genervon Biopharmaceuticals, LLC, a clinical stage biopharmaceutical company, proposes multiple grand challenges to provide biological drugs to meet many unmet critical medical needs of the world. 

Genervon has discovered and developed new classes of novel master regulators biological drugs. These proprietary new classes of biological drugs are high level, human fetal stage, endogenous master regulators that modulate multiple pathways of gene expression useful to treat disorders and diseases in the nervous system and vascular system. Beyond these indications, Genervon is actively evaluating other diseases and indications such as cardiovascular, oncology, hematology and others not yet in the public domain. Genervon has obtained USA FDA approval to proceed with Phase II clinical trials for two CNS neuro-regeneration and neuro-protection indications. 

In order to fully exploit the potential of Genervon’s proprietary master regulators biological drugs discoveries and dramatically accelerate the drug approval process, Genervon is proposing the G2C to qualified scientists/clinicians to propose clinical trial Phase II protocols for the indication(s) they are specialized in and to propose preclinical studies protocols for the establishment of proof of concept. If the proposals and credentials are accepted by Genervon, the scientist/clinician will be given novel master regulator drug candidates appropriate for the study of the proposed indication to generate efficacy data from preclinical studies to allow Genervon to obtain IND approval*. The scientist/clinician is also to guide and support clinical trials conducted by Genervon to final approval*. 

US$1M will be awarded for each indication to each winning scientist/clinician after final Genervon and FDA approval to market the associated drug. US$100k will be awarded to each successful referral approved by Genervon. Orphan drug indications are welcome.

* Scientist/clinician does not have to get regulatory approvals or to conduct clinical trials.

For more information visit http://www.genervon.com.


Contact

Genervon Biopharmceuticals LLC
Dorothy Ko
COO
1055 E. Colorado Blvd. Suite 500
Pasadena, CA 91106
Tel: (323)-721-5500
This e-mail address is being protected from spambots. You need JavaScript enabled to view it .